Fertility and Sterility
Volume 92, Issue 6 , Pages 1953-1959, December 2009

Patients with severe ovarian hyperstimulation syndrome can be managed safely with aggressive outpatient transvaginal paracentesis

Boston IVF, Waltham, Massachusetts, and Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts

Received 20 July 2008; received in revised form 3 September 2008; accepted 3 September 2008. published online 31 October 2008.

Objective

To describe our experience with aggressive outpatient transvaginal paracentesis to manage ovarian hyperstimulation syndrome (OHSS).

Design

Retrospective case series.

Setting

Private, academically affiliated IVF center.

Patient(s)

Women undergoing assisted reproductive technologies (ART) and having a diagnosis of OHSS.

Intervention(s)

Management of OHSS with hospitalization or outpatient transvaginal paracentesis between 1999 and 2007.

Main Outcome Measure(s)

Grade and stage of OHSS, need for hospitalization, and adverse events.

Result(s)

From 1999 to 2007, we identified 183 patients with OHSS. We began performing outpatient transvaginal paracentesis to treat OHSS in 2002. We have performed 146 outpatient transvaginal paracenteses in 96 patients with no procedure-related complications. With the implementation of early, aggressive, outpatient paracentesis, the number of patients requiring hospitalization for OHSS decreased. From 2006 to 2007, 29 patients were diagnosed with severe OHSS and 25 (86%) were managed as outpatients with transvaginal paracentesis with no complications.

Conclusion(s)

This report represents one of the largest series of patients with OHSS managed with outpatient transvaginal paracentesis. Although there continues to be a small percentage of patients with OHSS who require hospitalization, the vast majority of patients with severe OHSS at our center in the past 2 years had their condition successfully managed as outpatients with use of aggressive transvaginal paracentesis.

Key Words: Ovarian hyperstimulation syndrome, paracentesis

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 L.P.S. has nothing to disclose. M.R.H. is a member of the Data Monitoring Committee for Bayer Healthcare Pharmaceuticals, Inc. M.M.A. is a consultant and lecturer for EMD Serono and for Organon, Inc., and performs research for Gene Security.

 Accepted for poster presentation at the American Society for Reproductive Medicine Annual Meeting, San Francisco, California, November 8–12, 2008.

PII: S0015-0282(08)03894-6

doi:10.1016/j.fertnstert.2008.09.011

Fertility and Sterility
Volume 92, Issue 6 , Pages 1953-1959, December 2009